Dr. Beer on the Implications of the PREVAIL Study
Автор: OncLive
Загружено: Feb 3, 2014
Просмотров: 276 views
Tomasz Beer, MD, FACP, professor of Medicine, deputy director of the Knight Cancer Institute, Oregon Health and Science University, discusses the treatment of metastatic castration-resistant prostate cancer (mCRPC) with abiraterone and enzalutamide as it relates to results from the PREVAIL study.
More from this conference: http://www.onclive.com/conference-cov...

Доступные форматы для скачивания:
Скачать видео mp4
-
Информация по загрузке: